The race for a COVID-19 is heating up. At least two COVID-19 vaccine makers ― Pfizer and Moderna ― may have enough clinical trial data to begin seeking U.S. regulatory approval in December, according to Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases.
“Somewhere around December, you will start to see companies with enough data… so they can move forward and apply for emergency-use authority from the FDA,” he told host Dr. Howard Bauchner at a Journal of the American Medical Association webcast on Oct. 28. “Then it could be granted. It could be January, or it could be later.” Continue reading
Chart: AHCJ Right to Know Committee Source: “Covering Covid” Survey | Fall 2020See more graphics of survey results below.
Reporters covering the COVID-19 pandemic have often been unable to speak directly with public health experts, hindering access to complete and accurate information, according to results of AHCJ’s “Covering Covid” survey.
Nearly half of respondents reported that “always,” “most of the time” or “about half the time” they had been blocked from speaking with public health experts. More than half said that press briefings in their area have been led by politicians rather than health experts, and those briefings often failed to answer critical questions. Continue reading
Photo: NIH Image Gallery via FlickrElectron micrograph of two cytotoxic T cells (red) attacking an oral squamous cancer cell (white), part of a natural immune response.
If you write anything about cancer treatment, it’s nearly impossible to avoid writing about immunotherapy. But reporting on immunotherapy can quickly become complex, confusing and overwhelming. A new AHCJ tip sheet on cancer immunotherapy can help you to report effectively and appropriately on the topic.
The therapy is exactly what it sounds like. Cancer immunotherapy works to recruit the patient’s immune system to fight the cancer instead of using chemotherapy to kill cancer cells directly. Continue reading
If you are looking for an undercovered story during this pandemic, take a look at the continued threat of antibiotic-resistant pathogens.
There isn’t a lot of data out there, but scientists are watching for signs that COVID-19 patients are being overtreated with antibiotics, which could lead to a surge in super bugs – the term for bacteria and fungus that are resistant to most, if not all, antibiotics.
Over the years, I’ve presented on reporting medical research findings. Some of the most common questions I get are about writing the findings using accessible language that an average person can understand. It’s particularly difficult when the outcome is reported in units like standard deviations, but reporting hazard ratios and odds ratios can be confusing as well, especially for those who only occasionally write about medical studies.
A new resource from the Winton Centre for Risk and Evidence Communication at Cambridge University in the UK can help you make sense of those findings and even provide the language and graphics to help your audience understand the results. RealRisk is the brainchild of professor David Spiegelhalter, the center’s chair, a statistician and author of The Art of Statistics, and Executive Director Alexandra Freeman, who told me more about the tool. Continue reading
The U.S. Supreme Court this month heard oral arguments in the case of Rutledge v. Pharmaceutical Care Management Association. At issue is the right of states to regulate pharmacy benefit management (PBMs) companies, which employers and health plans hire as middlemen to manage their prescription benefit programs for workers and other plan members.
During oral arguments on Oct. 6, several justices asked about the burden that health plans encounter when PBM regulations differ from one state to another, as Rachel Cohrs reported for Modern Healthcare. Continue reading